Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Petros Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Petros Pharmaceuticals, Inc.

PTPI

Petros Pharmaceuticals, Inc.

About Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals develops innovative healthcare technology platforms to facilitate Rx-to-OTC drug switches. Its primary focus is on creating SaaS and SaMD solutions that help pharmaceutical companies navigate regulatory approval, enhance consumer self-selection, and expand access to nonprescription medications. The company licenses its proprietary technology, targeting the self-care market and emerging health tech collaborations, while shifting away from direct product sales.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Petros Pharmaceuticals, Inc.

1
1
Petros Pharmaceuticals, Inc. Petros Pharmaceuticals Reports Reduced Net Loss and Strategic Shift Amid Liquidity Concerns

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Petros Pharmaceuticals, Inc. Petros Pharmaceuticals Reports $1.9 Million Net Income for Fiscal Year 2025, Plans Strategic Shift to OTC Market

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
Petros Pharmaceuticals, Inc. Petros Pharmaceuticals Reports $2.25 Million Net Income for Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Petros Pharmaceuticals, Inc. Petros Pharmaceuticals Reports $3.2 Million Net Income Turnaround Amid Restructuring Efforts

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Petros Pharmaceuticals, Inc. Petros Pharmaceuticals Reports $2.26 Million Net Loss in Q1 2025 Amid Strategic Transition

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Petros Pharmaceuticals, Inc. Petros Pharmaceuticals Reports Revenue Decline and Strategic Shift Amid Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Petros Pharmaceuticals, Inc. Petros Pharmaceuticals Reports 29% Decline in Net Sales, Net Loss of $16.01 Million in Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments